Pharmaceutical

Viatris gains China approval for Yupelri to treat COPD

Theravance Biopharma’s partner Viatris has received China's NMPA approval for Yupelri inhalation solution for maintenance treatment of COPD.

Jun 29, 2025 - 06:00
Viatris gains China approval for Yupelri to treat COPD
Theravance Biopharma’s partner Viatris has received China's NMPA approval for Yupelri inhalation solution for maintenance treatment of COPD.
Read the original article

Tags:

Previous Article

AI in drug discovery: from hypothetical to reality

Next Article

Novo Nordisk teams up with WeightWatchers in latest telehealth push

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Scientists develop largest ever biological AI model that ‘thinks in nucleotides’

Scientists develop largest ever biological AI model tha...

Feb 21, 2025

CPHI Europe: Overcoming the unique challenges with high-concentration mAbs

CPHI Europe: Overcoming the unique challenges with high...

Oct 12, 2024

STAT+: Rune Labs, which makes an app to track Parkinson’s symptoms, raises $12 million

STAT+: Rune Labs, which makes an app to track Parkinson...

Jan 12, 2024